Cite
HARVARD Citation
Tan, W. et al. (2018). N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group (NCCTG) Trial. Annals of oncology. p. 2150. [Online].